Samer Alsaid: Warfarin Outcomes Reassessed Through COMBINE AF
Samer Alsaid, Cardiologist and Vascular Medicine Specialist, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC: Advances, adding:
“Some projects become more than just papers.
Three years ago, my first project at the TIMI Study Group began with a long-standing idea of Dr. Eugene Braunwald.
He had long recognized that we had one of the world’s largest collections of patients treated with warfarin from the pivotal atrial fibrillation trials—and a unique opportunity to answer questions that remain clinically relevant today, including whether there are patients for whom warfarin may still be a reasonable option, particularly where access to DOACs is limited.
Three years later, that work has culminated in two companion papers from the COMBINE AF collaboration, now published in JACC: Advances.
Dr. Braunwald mentored this work every step of the way—with calls, ideas, and thoughtful edits—until the very end.
Sadly, he did not live to see these papers published.
His mentorship, intellectual curiosity, and unwavering commitment to improving patient care will stay with me for the rest of my career.”
Title: Outcomes With Warfarin in Atrial Fibrillation: Individual Patient Data Analysis From Four Randomized Trials
Authors: Samer AlSaid, Eugene Braunwald, Elaine M. Hylek, Michael G. Palazzolo, Andrea Bellavia, Elliott M. Antman, Anthony P. Carnicelli, John W. Eikelboom, Christopher B. Granger, Manesh R. Patel, Lars Wallentin, Christian T. Ruff, Robert P. Giugliano
Read the full article on JACC: Advances.
Title: Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation
Authors: Samer Al Said, Andrea Bellavia, Eugene Braunwald, Elaine M. Hylek, Michael G. Palazzolo, Hwanhee Hong, Elliott M. Antman, Anthony P. Carnicelli, John W. Eikelboom, Christopher B. Granger, Manesh R. Patel, Lars Wallentin, Christian T. Ruff, Robert P. Giugliano
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 14:27Isabella Presch: From Innovation to Accessibility in Cell and Gene Therapy
-
Oct 30, 2026, 14:00Abdul Mannan: A Negative PCR Does Not Exclude β-Thalassaemia
-
Oct 30, 2026, 13:53Matteo Foschi: Can Thrombolysis Safely Treat Stroke After Cardiac Procedures?
-
Oct 30, 2026, 13:42Wolfgang Miesbach: Gene Therapy-Associated Leukaemia With Clonal Persistence Over 16 Years
-
Oct 30, 2026, 12:47Louise St. Germain Bannon: Turning Thrombosis Awareness into Stroke Prevention
-
Oct 30, 2026, 12:36Aryabhatta Sadhu: Sickle Cell Crisis Recognising When Treatment Must Change
-
Oct 30, 2026, 12:22Fabrice Cognasse: The Future of Blood Banks From Transfusion Support to Precision Medicine
-
Oct 30, 2026, 12:09Carmelo Gurnari: Clonal Dynamics in the Bone Marrow During Sepsis and Emergency Haematopoiesis
-
Oct 30, 2026, 11:49Advancing Global Care for Hemophilia and Bleeding Disorders – World Federation of Hemophilia